<DOC>
	<DOCNO>NCT01668524</DOCNO>
	<brief_summary>This single-site , dose-escalation study evaluate safety tolerability increase concentration ATS907 12 subject Primary Open Angle Glaucoma and/or Ocular Hypertension</brief_summary>
	<brief_title>ATS907 Ph2a Open-Label Dose-ranging Safety Tolerability Primary Open Angle Glaucoma ( POAG ) Ocular Hypertension ( OHT ) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<criteria>18 year age great Diagnosis open angle glaucoma ocular hypertension eye Corrected visual acuity eye +1.0 logMAR good Early Treatment Diabetic Retinopathy Study ( EDTRS ) eye ( equivalent 20/200 ) Must willing discontinue use ocular hypotensive medication eye prior entire course study Ophthalmic ( either eye ) : Glaucoma : pseudoexfoliation , steroid induce , pigment dispersion glaucoma , history angle closure . Previous glaucoma intraocular surgery glaucoma laser procedure study eye ( ) . Refractive surgery study eye Cataract surgery intraocular surgery within one month prior Screening either eye History within 3 month prior Screening clinically significant moderate severe chronic active ocular infection , inflammation , blepharitis , dermatitis , uveitis conjunctivitis Clinically significant corneal dystrophy , epithelial endothelial disease , corneal irregularity scar reliable applanation tonometry would prevent Contact lens wear duration study Clinically significant ocular disease ( e.g. , diabetic retinopathy , macular degeneration , uveitis ) might interfere progress study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>